Hyperuricemia linked to higher mortality in chronic kidney disease patients

Hyperuricemia, a condition characterized by elevated uric acid levels in the blood, has been identified as an independent predictor of mortality among patients with chronic kidney disease (CKD). The finding was reported in a study published online on July 13 in the *Journal of Clinical Medicine*, adding to the growing evidence that metabolic abnormalities contribute significantly to adverse outcomes in CKD populations.

In the investigation, researchers analyzed data from a large cohort of CKD patients, adjusting for traditional risk factors such as age, sex, blood pressure, and kidney function. Even after accounting for these variables, higher serum uric acid concentrations remained significantly associated with an increased risk of death. The study’s authors suggest that hyperuricemia may reflect underlying pathophysiological processes—such as inflammation, oxidative stress, or endothelial dysfunction—that accelerate disease progression and elevate mortality risk.

These results underscore the importance of monitoring uric acid levels in CKD management and may prompt clinicians to consider targeted interventions. While further research is needed to determine whether lowering uric acid can improve survival, the study highlights hyperuricemia as a clinically relevant marker that could help identify patients at greater risk of adverse outcomes.